DNA Genotek v. Spectrum Solutions: Appeal 24-1840 Dismissed in 37 Days
DNA Genotek, Inc. voluntarily dismissed its Federal Circuit appeal over US11,002,646 — a patent covering sample collection devices and solutions — after a joint stipulation confirmed each side bears its own costs. DNA Genotek simultaneously conceded that all claims of US11,002,646 it had been asserting are unpatentable, reducing the companion appeal (2023-2017) to a single remaining patent.
A patent conceded unpatentable — and what that leaves behind
Filed 21 May 2024 at the Court of Appeals for the Federal Circuit, Appeal No. 24-1840 pitted DNA Genotek, Inc. against Spectrum Solutions, LLC over US Patent No. 11,002,646 — a patent directed to devices, solutions and methods for biological sample collection. The appeal arose from an invalidity or cancellation action, with patentability of the ‘646 patent at the centre of the dispute.
The case closed on 27 June 2024, just 37 days after filing, via a joint stipulation of voluntary dismissal under Fed. R. App. P. 42(b)(1). Each party agreed to bear its own costs. No merits panel reached the substantive patentability questions, meaning the Federal Circuit issued no ruling on the validity of the ‘646 patent’s claims.
What makes this dismissal commercially significant is DNA Genotek’s own admission in companion appeal 2023-2017: the company stated that ‘all the claims in [US11,002,646] that Genotek had been asserting are unpatentable.’ The public record does not disclose what triggered that concession — whether IPR proceedings, claim mapping failures, or a litigation cost-benefit calculation — but the effect is clear: US11,002,646 is effectively neutralised as an enforcement asset.
Filing to Appeal Dismissed in 37 days
37 days — unusually swift resolution, consistent with a pre-briefing voluntary dismissal
Appeal dismissed: what the joint stipulation means for both parties
Voluntary dismissal under Fed. R. App. P. 42(b)(1) — no merits ruling
A voluntary dismissal at the Federal Circuit under Rule 42(b)(1) terminates the appeal without adjudication on the merits. The court does not assess validity, infringement, or claim scope. Crucially here, the dismissal was accompanied by DNA Genotek’s own concession — in a separate filing — that all asserted claims of US11,002,646 are unpatentable, making this more than a procedural exit.
No merits adjudicationDNA Genotek loses US11,002,646 as an enforcement tool
By conceding that all asserted claims of US11,002,646 are unpatentable, DNA Genotek has effectively surrendered this patent’s commercial value. The public record does not specify whether the concession was with or without prejudice to the underlying invalidity proceedings, but the practical impact is that the ‘646 patent cannot credibly anchor future enforcement actions. Genotek’s remaining appellate exposure now centres solely on US10,619,187 in Appeal No. 2023-2017.
Patent enforcement neutralisedSpectrum Solutions achieves US11,002,646 clearance without a merits ruling
Spectrum Solutions obtains a commercially significant outcome — freedom from the ‘646 patent’s claims — without the Federal Circuit ever ruling on validity. The each-side-bears-own-costs structure suggests neither party extracted concessions beyond the dismissal itself. Spectrum still faces Appeal No. 2023-2017 over US10,619,187, meaning litigation risk in this technology space persists.
Partial clearance achievedSample collection IP landscape narrows — but one patent remains live
The effective cancellation of US11,002,646 claims reduces the patent thicket around biological sample collection devices and solutions, potentially broadening design freedom for competitors and new entrants in this space. However, US10,619,187 remains active in Appeal No. 2023-2017, meaning enforcement risk for sample collection technology is not fully resolved. Companies operating in this sector should monitor the companion appeal closely.
Sector risk partially reducedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | DNA Genotek, Inc. | Company | Biological sample collection technology company — holder of US11002646B2Search in Eureka ↗ |
| Defendant | Spectrum Solutions, LLC | Company | Spectrum Solutions, LLC — sample collection device manufacturer and litigation respondentSearch in Eureka ↗ |
| Plaintiff counsel | Brian M. Kramer | Attorney | Counsel for DNA Genotek, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Brian Robert Matsui | Attorney | Counsel for DNA Genotek, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Drew Alan Hillier | Attorney | Counsel for DNA Genotek, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Mehran Arjomand | Attorney | Counsel for DNA Genotek, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Seth W. Lloyd | Attorney | Counsel for DNA Genotek, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morrison & Foerster, LLP | Law Firm | Representing DNA Genotek, Inc.Search in Eureka ↗ |
| Defendant counsel | Ali S. Razai | Attorney | Counsel for Spectrum Solutions, LLCSearch in Eureka ↗ |
| Defendant counsel | Benjamin Bruce Anger | Attorney | Counsel for Spectrum Solutions, LLCSearch in Eureka ↗ |
| Defendant counsel | Benjamin J. Everton | Attorney | Counsel for Spectrum Solutions, LLCSearch in Eureka ↗ |
| Defendant counsel | Jeremiah Helm | Attorney | Counsel for Spectrum Solutions, LLCSearch in Eureka ↗ |
| Defendant counsel | Joseph F. Jennings | Attorney | Counsel for Spectrum Solutions, LLCSearch in Eureka ↗ |
| Defendant law firm | Knobbe Martens Olson & Bear, LLP | Law Firm | Representing Spectrum Solutions, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The order records that dismissal follows a joint stipulation under Fed. R. App. P. 42(b)(1), meaning the Federal Circuit exercised no appellate review of the district-level or PTAB-level patentability determination. The procedurally significant element is DNA Genotek’s accompanying statement — made in companion docket 2023-2017 — that all asserted ‘646 claims are unpatentable. This is not a neutral exit: it is a substantive concession that effectively functions as a validity determination for commercial and litigation monitoring purposes, even absent a formal court ruling.
US11002646B2 — biological sample collection devices and solutions
US Patent No. 11,002,646 (Application No. US16/879,506) covers devices, solutions and methods for biological sample collection — a technology domain central to DNA-based diagnostics, at-home testing kits, and biobank sample logistics. The patent sits within a rapidly commercialised space accelerated by demand for remote specimen collection. DNA Genotek conceded in the companion Federal Circuit appeal that all claims it had been asserting under this patent are unpatentable.
For competitors and new market entrants in the sample collection technology sector, the effective neutralisation of US11,002,646 is strategically significant. However, the companion patent US10,619,187 remains contested at the Federal Circuit, suggesting that the underlying technology space retains meaningful patent enforcement risk. Companies developing or licensing sample stabilisation or collection device technologies should treat the ‘646 clearance as partial, not total.
Should you run an FTO analysis against US11002646B2?
Any R&D team, procurement function, or product manager operating in the biological sample collection, DNA stabilisation, or at-home diagnostics space should assess the status of US11,002,646 before concluding it is fully cleared. While DNA Genotek’s concession of unpatentability is commercially powerful, the companion patent US10,619,187 is still being litigated — and related continuation or divisional applications in the same family may carry enforceable claims.
PatSnap Eureka’s FTO Search Agent can map the full patent family around US11,002,646 and US10,619,187, identify related pending applications, and flag claim-level overlap with your specific product design. For sample collection device teams, this is a fast-moving enforcement environment — automated docket monitoring in Eureka ensures you are alerted the moment Appeal No. 2023-2017 reaches a decision.
Run a freedom-to-operate analysis on US11002646B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit appeals in biological sample collection patent disputes
Federal Circuit invalidity appeals in biological sample collection and diagnostics technology — cases where patentability of device and solution claims was contested at the appellate level.
What this case signals for the sample collection IP landscape
A patent holder’s own concession of unpatentability is a rare and consequential event — with ripple effects beyond this single appeal.
Plaintiff concessions of unpatentability carry immediate FTO weight
When a patent holder publicly states that all asserted claims of a patent are unpatentable — as DNA Genotek did here — that admission can be cited in related proceedings and strengthens competitors’ freedom-to-operate positions. Companies in the sample collection space should document this concession in their IP risk registers.
Companion appeal 2023-2017 over US10,619,187 is now the key case to watch
With US11,002,646 neutralised, the Federal Circuit’s eventual ruling in Appeal No. 2023-2017 on US10,619,187 will define the remaining enforceability of DNA Genotek’s sample collection patent portfolio. Monitoring that docket is now a priority for any company designing or distributing sample collection devices.
DNA v Spectrum — key questions answered
Appeal No. 24-1840 was voluntarily dismissed at the Federal Circuit on 27 June 2024, just 37 days after filing. The parties filed a joint stipulation under Fed. R. App. P. 42(b)(1), with each side bearing its own costs. No merits ruling was issued. DNA Genotek separately conceded that all asserted claims of US11,002,646 are unpatentable.
The concession was made by DNA Genotek in a filing in companion Appeal No. 2023-2017. While it is not a formal court ruling, it constitutes a party admission that the claims lack patentability. This carries significant weight in FTO analysis and may be cited in related invalidity proceedings, though the public record does not confirm whether it forecloses all future enforcement paths.
Following the dismissal of Appeal No. 24-1840, Appeal No. 2023-2017 remains active at the Federal Circuit. DNA Genotek confirmed that the issues in that appeal are now narrowed to those relating to US Patent No. 10,619,187. The court’s order directed the clerk to transmit the dismissal order to the merits panel assigned to 2023-2017.
The broader dispute involves at least two patents: US11,002,646 (now conceded unpatentable by DNA Genotek, appeal dismissed) and US10,619,187 (still at issue in Federal Circuit Appeal No. 2023-2017). Both patents relate to devices, solutions and methods for biological sample collection.
The dismissal combined with DNA Genotek’s unpatentability concession provides meaningful FTO support for manufacturers operating in the sample collection device space with respect to US11,002,646 specifically. However, US10,619,187 remains contested, and related patent family members should be independently evaluated before concluding the space is fully clear.
PatSnap Eureka searches patents and litigation data to answer instantly.